Antibiotics Market Analysis

Antibiotics Market Analysis

To get key market trends

  Download Free Sample

Based on the drug class, the market is classified into penicillins, cephalosporins, macrolides, quinolones, aminoglycosides, tetracyclines, and other drug classes. The cephalosporins segment dominated the market with revenue of USD 14.1 billion in 2023.
 

• Cephalosporins, a beta-lactam antibiotic are widely used to treat conditions such as pneumonia, skin infections, and meningitis. Also, cephalosporins have undergone multiple generations of enhancement. Therefore, the continuous evolution of cephalosporin products is evident in strategic mergers and acquisitions anticipated to propel the market growth.
   
• For instance, in October 2021, Sandoz acquired GSK plc’s cephalosporin antibiotics business for USD 500 million, expanding their product line and addressing the rising incidence of infections. This strategic approach aimed in enhancing and broadening the capabilities of the cephalosporin business.
   

Based on type, the antibiotics market is classified into branded and generics. The branded segment held the highest market share of 55.3% in 2023.

• The high growth can be attributed to factors such as strong brand recognition, perceived quality, and innovative formulations. As pharmaceutical companies introduce and innovative patent formulations with often associated with extensive research and development, command a significant market share, offering unique formulations that contribute to their prominence and market leadership.
   

Based on spectrum, the antibiotics market is classified into broad-spectrum antibiotics and narrow-spectrum antibiotics. The broad-spectrum antibiotics segment is expected hold the highest revenue throughout the forecast period 2032.
 

• High versatility against a wide array of bacteria with both gram-positive and gram-negative strains has spurred the demand for broad-spectrum antibiotics. Similarly, the broad applicability in treating diverse infections has led to widespread usage, making them a cornerstone in addressing various bacterial illnesses, thereby contributing significantly to market growth.
   

Based on drug origin, the antibiotics market is classified into natural, semisynthetic, and synthetics. The natural segment accounted for USD 23.5 billion in 2023.
 

• The natural originated antibiotics, with inherent antimicrobial properties, have been fundamental in treating bacterial infections. Their historical efficacy and broad applicability underscored the enduring significance of natural sources in shaping the market.
   

Based on applications, the antibiotics market is categorized into respiratory infections, UTI, skin and soft tissue infections, sexually transmitted infections (STIs), gastrointestinal infections, and other applications. The UTI application is expected to lead the market, projecting the highest revenue of USD 23.3 billion by 2032.

• The high incidence of UTIs, particularly among women, propels the need for antibiotics such as ciprofloxacin and trimethoprim-sulfamethoxazole, crucial in managing these infections. For instance, as estimated in the BMC Infectious Diseases journal, UTIs rank as the second most prevalent infectious disease, impacting over 150 million individuals annually. Thus, driving the continuous reliance on antibiotics and making them a cornerstone in the pharmaceutical landscape.
   
• Additionally, ongoing antibiotic development addresses challenges associated with respiratory infections, thereby further contributing to market expansion.
   

Based on route of administration, the antibiotics market is classified into oral, parenteral, and other routes of administration. In 2023, the parenteral route leads the market anticipating its growth during the analysis period with a CAGR of 3.2%
 

• The parenteral route dominance was attributed due to its efficacy in delivering medications directly into the bloodstream through injections or intravenous infusions.
   
• The parenteral route ensured the rapid and precise drug distribution, making it crucial for treating severe infections or instances where oral absorption is compromised, thus contributing significantly to the widespread success of antibiotic therapies.
   

Based on distribution channel, the antibiotics market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is anticipated to secure the largest business share in 2023 and is anticipated to show similar trend during the analysis period.
 

• The active involvement in antimicrobial stewardship programs, ensuring precise prescriptions based on clinical need, susceptibility data, and guidelines, solidifies their influence. With the focus on optimal dosing for varied patient conditions, hospital pharmacies play a key role in shaping the antibiotic market landscape.
   

In 2023, North America secured a substantial business share in the antibiotics market and is expected to dominate throughout the forecast period.
 

• The region's strong position in the market stems from a high incidence of infectious diseases such as pneumonia and TB, securing a substantial market share.
   
• Additionally, the dominance is reinforced by governmental initiatives promoting safe and effective treatments. For instance, the FDA's May 2023 approval of Innoviva Inc.'s Xacduro addresses hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, providing a crucial solution for severe infections and expanding treatment options.